Premium
Safe and effective use of plerixafor plus G‐CSF in dialysis‐dependent renal failure
Author(s) -
Pinto Valeria,
Castelli Andrea,
Gaidano Gianluca,
Conconi Annarita
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21712
Subject(s) - medicine , family medicine
International audiencePlerixafor, a selective antagonist of the CXC chemokine receptor 4, is approved for hematopoietic stem cell mobilization in lymphoma and multiple myeloma patients who previously failed mobilization with the sole G-CSF. Reduced doses of the drug can be safely administered in cases of moderate renal impairment. However, the use of plerixafor in dialysis-dependent patients has not been reported. We report a case of safe administration of plerixafor in a patient with dyalisis-dependent renal failure complicating multiple myeloma and subsequent successful myeloablative chemotherapy with stem cell rescue. In our experience plerixafor might be safe and effective in combination with G-CSF in end-stage renal failure. The toxicity profile and optimal dose of the drug in this clinical setting should be assessed in large series of patients